within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AF03_Edoxaban;

model Edoxaban
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.62,
    Cl = 6.166666666666667e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.107,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0098,
    Tlag = 10.200000000000001,
    Vdp = 0.056299999999999996,
    k12 = 9.944444444444445e-06,
    k21 = 9.944444444444445e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Edoxaban</td></tr><tr><td>ATC code:</td><td>B01AF03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>107</td><td>L</td></tr>
    <tr><td>clearance:</td><td>22.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Edoxaban is an oral, direct factor Xa inhibitor anticoagulant used for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. It is approved in several countries including the US, EU, and Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after administration of 60 mg oral dose in healthy adult subjects (male and female).</p><h4>References</h4><ol><li><p>Elenjickal, EJ, et al., &amp; Mavrakanas, TA (2024). Anticoagulation in Patients with Chronic Kidney Disease. <i>American journal of nephrology</i> 55(2) 146–164. DOI:<a href=\"https://doi.org/10.1159/000535546\">10.1159/000535546</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38035566/\">https://pubmed.ncbi.nlm.nih.gov/38035566</a></p></li><li><p>Martin, KA, et al., &amp; Moll, S (2017). Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. <i>The American journal of medicine</i> 130(5) 517–524. DOI:<a href=\"https://doi.org/10.1016/j.amjmed.2016.12.033\">10.1016/j.amjmed.2016.12.033</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28159600/\">https://pubmed.ncbi.nlm.nih.gov/28159600</a></p></li><li><p>Dunois, C (2021). Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). <i>Biomedicines</i> 9(5) –. DOI:<a href=\"https://doi.org/10.3390/biomedicines9050445\">10.3390/biomedicines9050445</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33919121/\">https://pubmed.ncbi.nlm.nih.gov/33919121</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AF03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Edoxaban;
